A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...

Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...

OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...

The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3 KEYNOTE-B96 trial in which the ...

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran ...